Biopharma scores a $5bn quarter as another big year builds for venture financing.
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.
A sudden increase in seed and series A funding bodes well for the year ahead.
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
But financing sizes have grown by a similar amount on both sides of the Atlantic.
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.